ProteinQure develops breakthrough Peptide Drug Conjugate for triple-negative breast cancer using computational platform.

ProteinQure, a computational drug design startup, has announced a breakthrough in the development of a novel Peptide Drug Conjugate (PDC) targeting triple-negative breast cancer (TNBC). The PDC, developed using ProteinQure's computational platform, demonstrated remarkable efficacy in Patient-Derived Xenograft (PDX) models, including cancers resistant to standard chemotherapies and antibody-drug conjugates. The findings will be presented at the American Association for Cancer Research conference.

March 25, 2024
3 Articles